Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S ®), an investigational folate receptor alpha ...

BOSTON, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Precede Biosciences, a company advancing precision medicine through its first-in-class comprehensive epigenomic liquid biopsy platform, today announced the ...

The ongoing CRB-701 Phase 1/2 clinical trial ( NCT06265727) is evaluating the safety, pharmacokinetics, and efficacy of CRB-701 in patients with advanced solid tumors known to be associated with high ...

The data represent the first clinical trial results of a 212Pb-based PSMA therapy. The findings support the further development of 212Pb-ADVC001 and may offer a new reference point in the treatment ...

Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups ; Median PFS was 15.5 months in the 120 mg palazestrant cohort ...

Novel regimen GO-4, combining melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cells shows manageable adverse reactions and a strong signal of efficacy in patients with ...

The six-month rPFS rate and median rPFS for patients from both arms combined was 67% and 9.1 months, respectively. For patients treated with 120 mg gedatolisib, the six-month rPFS rate was 74% and ...

Kura Oncology to host a virtual investor event today, October 18, 2025, at 10:30 a.m. PT / 1:30 p.m. ET / 7:30 p.m. CEST ...

Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with ...

Earlier this month, Company CEO Ryoji Baba was officially invited by the Embassy of Japan in Vietnam and appointed as a Board Member of United Nations-affiliated non-governmental organization (“NGO”) ...

Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding its clinical development in IgA nephropathy; JADE101 is an investigational, p ...

Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment option for patients; Vision improvements ...